A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia

By afschroeder • September 9, 2025

Aribi A, Mannis GN, Madanat YF, Jonas BA, Dunavin N, Roboz GJ, Jeyakumar D, Garcia-Manero G, Liu H, Carraway HE, Saultz JN, Blum W, Schiller G, Huang T, Woodard P, Klencke B, Liao XC, Xiang H, Pollyea DA, DiNardo CD. A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia. Blood Neoplasia. 2025 Jun 9;2(4):100126. doi: 10.1016/j.bneo.2025.100126. PMID: 40919482; PMCID: PMC12409809.

Tags: Hematology/Oncology, Publications

Social wellbeing, loneliness, and symptom burden in head and neck cancer survivors: a latent class analysis

Brauer ER, Choi KR, Petersen L, Ganz PA, St John MA, Wong DJ, Martin EJ. Social wellbeing, loneliness, and symptom burden in head and neck[...]

Achieving timely treatment for early-stage non-small cell lung cancer: Factors associated with delayed surgical resection and proposed quality benchmarks

Tupper HI, Bhattacharjee J, Sarovar V, Amara D, Schmittdiel JA, Quesenberry CP, Cummings AL, Velotta JB, Sakoda LC. Achieving timely treatment for early-stage non-small cell[...]

Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial

Abdelrahim M, Khan G, Hatoum H, Zervoudakis A, Dayyani F, Zhang L, Li J, Maxwell F, O'Reilly EM, Wainberg ZA, Bullock A. Impact of UGT1A1*28polymorphism in[...]